NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (the "Company" or "HSDT"), today announced its continued acquisition of Solana (“SOL”) tokens as part of its digital asset treasury strategy. The Company now holds over 2.2 million SOL. The Company also holds in excess of $15 million of cash, which it intends to use to further the digital asset treasury strategy. The Company’s combined Solana holdings (at $232.50 per SOL as of October 6^th at 12:00AM ET) and cash holdings exceed $525mm of value, exceeding the amount of gross proceeds from the initial private placement offering that closed on September 18^th.

These SOL purchases underscore HSDT’s commitment to the Company’s Solana treasury strategy and long-term confidence in the Solana ecosystem.

“Following in the footsteps of Michael Saylor at MSTR and Tom Lee at BMNR, HSDT Solana Company is focused on maximizing shareholder value by efficiently accumulating Solana. As evidence of that focus on efficient accumulation, HSDT’s Solana and cash holdings now exceed the initial capital raise amount in less than three weeks,” said Cosmo Jiang, General Partner at Pantera Capital and Board Observer at HSDT.

“HSDT Solana Company’s investment narrative is resonating with institutional investors. We are encouraged by the strong interest coming out of Asia after the major digital assets conferences last week, and we look forward to continuing to be a leading advocate for the Solana ecosystem to a whole new set of investors,” said Joseph Chee, Executive Chairman of HSDT and Chairman of Summer Capital.

Solana has historically been the fastest growing blockchain, leading the industry in transaction revenue and processing more than 3,500 transactions per second. The network is also the most widely adopted, averaging about 3.7 million daily active wallets and surpassing 23 billion transactions year to date. SOL is financially productive by design, offering a ~7% native staking yield, whereas assets like BTC are non-yield-bearing. As an independent treasury company, HSDT’s mission is to support the growth and security of tokenized networks by serving as a long-term holder of $SOL, in addition to continuing the development of its neurotech and medical device operations.

Forward Looking Statements

This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. This press release also includes express and implied forward-looking statements regarding the Company's current expectations, estimates, opinions and beliefs that are not historical facts. Such forward-looking statements may be identified by words such as "believes," "expects," "endeavors," "anticipates," "intends," "plans," "estimates," "projects," "should" and "objective" and the negative and variations of such words and similar words. These statements are made on the basis of current knowledge and, by their nature, involve numerous assumptions and uncertainties. Nothing set forth herein should be regarded as a representation, warranty or prediction that we will achieve or are likely to achieve any particular future result. Actual results may differ materially from those indicated in the forward-looking statements because the realization of those results is subject to many risks and uncertainties, including the risk that we may fail to realize the anticipated benefits of the private placement, including the ability of the Company to execute on its digital asset treasury strategy, as well as risks related to economic conditions, fluctuations in the market price of SOL, and the evolving regulatory environment, as well as other factors. Forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no duty to update such information except as required under applicable law.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator. For more information about the PoNS® or Helius Medical Technologies, visit www.heliusmedical.com.

The Company has adopted a digital asset treasury strategy focused on accumulating SOL, the native digital asset of the Solana blockchain, leveraging capital markets raises that produce consistent on-chain yield generation. Helius will provide access to the Solana network.

Media Contact